ABIOMED INC (ABMD) Fundamental Analysis & Valuation

NASDAQ:ABMD • US0036541003

Current stock price

381.02 USD
+0.23 (+0.06%)
At close:
381.3 USD
+0.28 (+0.07%)
After Hours:

This ABMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ABMD Profitability Analysis

1.1 Basic Checks

  • ABMD had positive earnings in the past year.
  • In the past year ABMD had a positive cash flow from operations.
ABMD Yearly Net Income VS EBIT VS OCF VS FCFABMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

1.2 Ratios

  • The Return On Assets of ABMD (15.72%) is better than 94.52% of its industry peers.
  • Looking at the Return On Equity, with a value of 17.32%, ABMD belongs to the top of the industry, outperforming 93.61% of the companies in the same industry.
  • The Return On Invested Capital of ABMD (12.19%) is better than 89.95% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ABMD is significantly above the industry average of 9.15%.
  • The last Return On Invested Capital (12.19%) for ABMD is well below the 3 year average (29.16%), which needs to be investigated, but indicates that ABMD had better years and this may not be a problem.
Industry RankSector Rank
ROA 15.72%
ROE 17.32%
ROIC 12.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ABMD Yearly ROA, ROE, ROICABMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 5 10 15 20 25

1.3 Margins

  • Looking at the Profit Margin, with a value of 24.84%, ABMD belongs to the top of the industry, outperforming 95.43% of the companies in the same industry.
  • ABMD's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 23.66%, ABMD belongs to the top of the industry, outperforming 93.61% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ABMD has grown nicely.
Industry RankSector Rank
OM 23.66%
PM (TTM) 24.84%
GM N/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
ABMD Yearly Profit, Operating, Gross MarginsABMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. ABMD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ABMD is creating value.
  • ABMD has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABMD Yearly Shares OutstandingABMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ABMD Yearly Total Debt VS Total AssetsABMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

  • ABMD has an Altman-Z score of 68.47. This indicates that ABMD is financially healthy and has little risk of bankruptcy at the moment.
  • ABMD's Altman-Z score of 68.47 is amongst the best of the industry. ABMD outperforms 99.54% of its industry peers.
  • ABMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 68.47
ROIC/WACC1.34
WACC9.07%
ABMD Yearly LT Debt VS Equity VS FCFABMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 7.93 indicates that ABMD has no problem at all paying its short term obligations.
  • ABMD has a better Current ratio (7.93) than 83.11% of its industry peers.
  • A Quick Ratio of 7.17 indicates that ABMD has no problem at all paying its short term obligations.
  • The Quick ratio of ABMD (7.17) is better than 82.19% of its industry peers.
Industry RankSector Rank
Current Ratio 7.93
Quick Ratio 7.17
ABMD Yearly Current Assets VS Current LiabilitesABMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ABMD Growth Analysis

3.1 Past

  • ABMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
  • The Earnings Per Share has been growing by 30.92% on average over the past years. This is a very strong growth
  • ABMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
  • ABMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.30% yearly.
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%

3.2 Future

  • ABMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.71% yearly.
  • The Revenue is expected to grow by 11.13% on average over the next years. This is quite good.
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ABMD Yearly Revenue VS EstimatesABMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
ABMD Yearly EPS VS EstimatesABMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. ABMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 78.72, which means the current valuation is very expensive for ABMD.
  • Based on the Price/Earnings ratio, ABMD is valued a bit cheaper than 71.69% of the companies in the same industry.
  • ABMD is valuated expensively when we compare the Price/Earnings ratio to 26.86, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 66.96, which means the current valuation is very expensive for ABMD.
  • Based on the Price/Forward Earnings ratio, ABMD is valued a bit cheaper than the industry average as 73.06% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 37.39. ABMD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 78.72
Fwd PE 66.96
ABMD Price Earnings VS Forward Price EarningsABMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 69.41% of the companies in the same industry are more expensive than ABMD, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, ABMD is valued cheaper than 80.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 79.09
EV/EBITDA 55.82
ABMD Per share dataABMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • ABMD has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ABMD's earnings are expected to grow with 14.00% in the coming years.
PEG (NY)20.54
PEG (5Y)2.55
EPS Next 2Y9.68%
EPS Next 3Y14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABMD Dividend Analysis

5.1 Amount

  • ABMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ABMD Fundamentals: All Metrics, Ratios and Statistics

ABIOMED INC

NASDAQ:ABMD (12/21/2022, 8:15:55 PM)

After market: 381.3 +0.28 (+0.07%)

381.02

+0.23 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-01
Earnings (Next)02-01
Inst Owners0%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change0%
Market Cap17.18B
Revenue(TTM)1.07B
Net Income(TTM)266.76M
Analysts70
Price Target375.36 (-1.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.37%
Min EPS beat(2)-5.24%
Max EPS beat(2)15.98%
EPS beat(4)3
Avg EPS beat(4)8.26%
Min EPS beat(4)-5.24%
Max EPS beat(4)15.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.37%
Min Revenue beat(2)-16.89%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.39%
Min Revenue beat(4)-16.89%
Max Revenue beat(4)-6.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.09%
PT rev (3m)N/A
EPS NQ rev (1m)4.13%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.46%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-3.26%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.36%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 78.72
Fwd PE 66.96
P/S 16
P/FCF 79.09
P/OCF 68.45
P/B 11.16
P/tB 12.15
EV/EBITDA 55.82
EPS(TTM)4.84
EY1.27%
EPS(NY)5.69
Fwd EY1.49%
FCF(TTM)4.82
FCFY1.26%
OCF(TTM)5.57
OCFY1.46%
SpS23.82
BVpS34.15
TBVpS31.36
PEG (NY)20.54
PEG (5Y)2.55
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 15.72%
ROE 17.32%
ROCE N/A
ROIC 12.19%
ROICexc 25.66%
ROICexgc 30.76%
OM 23.66%
PM (TTM) 24.84%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-10.63%
ROICexgc growth 5Y-2.2%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 122.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 81.43%
Current Ratio 7.93
Quick Ratio 7.17
Altman-Z 68.47
F-Score6
WACC9.07%
ROIC/WACC1.34
Cap/Depr(3y)188.19%
Cap/Depr(5y)276.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)138.14%
Profit Quality(5y)123.31%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
EBIT growth 1Y-2.58%
EBIT growth 3Y4.52%
EBIT growth 5Y23.29%
EBIT Next Year13.8%
EBIT Next 3Y20.3%
EBIT Next 5Y16.96%
FCF growth 1Y-11.7%
FCF growth 3Y6.24%
FCF growth 5Y31%
OCF growth 1Y-11.94%
OCF growth 3Y4.21%
OCF growth 5Y19.91%

ABIOMED INC / ABMD Fundamental Analysis FAQ

What is the fundamental rating for ABMD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ABMD.


What is the valuation status of ABIOMED INC (ABMD) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIOMED INC (ABMD). This can be considered as Overvalued.


What is the profitability of ABMD stock?

ABIOMED INC (ABMD) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for ABMD stock?

The Earnings per Share (EPS) of ABIOMED INC (ABMD) is expected to grow by 3.83% in the next year.